News

WASHINGTON, D.C. – Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, along with Reps. Palmer (AL-06), Carter (GA-01), Bilirakis (FL-12), and Obernolte (CA-23), penned a letter to the Executive Director of Covered California (CoveredCA), Jessica Altman, to request further information related to the potentially unauthorized transmission of sensitive personal health information involving Covered California’s website. Key Letter Excerpt: “According to public reports and agency statements, tracking technology was embedded on Covered California's website beginning in February 2024, as part of a broader digital advertising effort, and in direct contravention of the tracking platform’s user agreement, which prohibits the use of such tools on pages that collect sensitive health information. Although the tags were reportedly removed in April 2025, following external scrutiny and a vendor transition, the extended period of data exposure raises serious questions about the adequacy of safeguards that Covered California had in place. Forensic testing by investigative reporters identified the trackers in operation and confirmed that user-entered health information was being transmitted to third parties without consent. These circumstances warrant examination of Covered California’s actions under federal privacy standards.” “Ensuring the confidentiality of health information is a foundational obligation for entities operating within the health insurance ecosystem. Federal privacy protections, particularly the Health Insurance Portability and Accountability Act (HIPAA), establish expectations for how covered organizations handle sensitive data. Recent reports and public filings raised questions about whether those expectations were met in this case, and whether existing oversight mechanisms are sufficient to detect and prevent improper disclosures.” Background: Forensic testing shows Covered California —the State of California’s official health insurance marketplace—has been sending sensitive user health data to third-party websites through several online data trackers. Prior to removal of the trackers, CoveredCA had more than 60 trackers active on its website; the average number of trackers on a government website is three. Some types of information sent to such websites include: Searches for doctors in network with specific plans/specializations Demographic information, including gender, ethnicity, and martial status Length of treatment a patent received by a provider Frequency of doctor visits If the user indicated they were blind, pregnant, a victim of domestic abuse, or used prescription medications. The State of California independently operates CoveredCA. As the state’s official ACA marketplace, CoveredCA falls under the purview of Health Insurance Portability and Accountability Act (HIPAA). The disclosure of information such as pregnancy or prescription drug use without proper consent—even for “marketing purposes”—may violate HIPAA. This Congress, the Committee has sent letters to 23andMe and DeepSeek over potential data privacy concerns: The Committee also held a hearing last Congress on the Change Healthcare hack, where personal health information was also jeopardized. CLICK HERE to read Fox News coverage of the letter. CLICK HERE to view the full letter. ###

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, announced a hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget . “The recent passage of the OBBBA was an incredible example of how we are strengthening, securing, and sustaining our government health programs under President Trump,” said Chairmen Guthrie and Carter. “ Next week’s hearing gives us the opportunity to examine ways in which we can further incorporate health innovation, expand access to affordable care, and make America healthy again.” Subcommittee on Health hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget WHAT: Subcommittee on Health hearing on Department of Health and Human Services FY26 Budget. DATE: Tuesday, June 24, 2025 TIME: 10:00 AM ET LOCATION: 2123 Rayburn House Office Building This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be livestreamed online at energycommerce.house.gov . If you have any questions concerning this hearing, please contact Annabelle Huffman at Annabelle.Huffman@mail.house.gov . If you have any press-related questions, please contact Katie West at Katie.West@mail.house.gov . ###

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, released the following statement after President Donald Trump signed three resolutions of disapproval under the Congressional Review Act, which repeal disastrous electric vehicle (EV) mandates.  “By rejecting EV mandates, the signing of these resolutions is a victory for American consumers who reject government mandates and one-size-fits-all policies,”  said Chairman Guthrie.  “Without this repeal, the special rules for California would have led to higher prices on both new and used vehicles, furthered our dependence on China, and overwhelmed our already-strained electric grid. Instead, Congressional Republicans and President Trump are standing up for American consumers by rolling back the worst policies of the Biden-Harris Administration. Thank you to Vice Chairman Joyce, Congressman Obernolte, and Congressman James for your work to ensure that families and businesses can continue choosing the vehicles they need.” Read an Op-Ed from Chairman Guthrie, Vice Chairman Joyce, Congressman James, and Congressman Obernolte on these resolutions  here . Background: The Clean Air Act generally preempts individual states from setting their own vehicle emission standards. However, section 209 of the Clean Air Act allows the Environmental Protection Agency to waive state preemption for California. This carveout was intended to allow California to implement stricter air vehicle emission standards to address “compelling and extraordinary circumstances” involving local air pollution – not to remake the auto industry and limit consumer choice nationwide. The Biden-Harris EPA granted these waivers that have allowed California to ban sales of new gas, diesel, and hybrid vehicles, as well as heavy-duty trucks, while also mandating 100% electric vehicle sales by 2035. H.J. Res. 88, led by Rep. John Joyce (PA-13), Vice Chairman of the House Committee on Energy and Commerce, repeals California’s Advanced Clean Cars II (ACCII) waiver, which would have the State to ban the sale of gas-powered vehicles by 2035. H.J. Res. 87, led by Rep. John James (MI-10), repeals California’s Advanced Clean Trucks (ACT) waiver, which would have allowed the State to mandate the sale of zero-emission trucks. H.J. Res. 89, led by Rep. Jay Obernolte (CA-23), puts an end to California’s implementation of its most recent nitrogen oxide (NOx) engine emission standards, which would have created burdensome and unworkable standards for heavy-duty, on-road engines. ###

WASHINGTON, D.C.  – Congressman Gus Bilirakis (FL-12), Chairman of the Subcommittee on Commerce, Manufacturing, and Trade, delivered the following opening statement at today’s hearing titled  Winning Off the Field: Legislative Proposal to Stabilize NIL and College Athletics. Subcommittee Chairman Bilirakis' opening statement as prepared for delivery: “Good morning, everyone, and welcome to our legislative hearing on Name, Image, and Likeness in college athletics.  “I want to thank our witnesses for being here today. Your experience and insight are critical as we navigate what is arguably one of the most transformative moments in the history of college sports.  “In recent years, we’ve seen a dramatic shift in how college athletes engage with their sports, their schools, and their personal brands. The recent House v. NCAA settlement represents more than just a court decision — it marks a fundamental change in how college athletics will operate going forward. The timing couldn’t be more appropriate for legislative action. “That’s why I am leading the SCORE Act — the Student Compensation and Opportunity through Rights and Endorsements Act — a comprehensive, commonsense discussion draft that reflects months of dialogue with student-athletes, athletic directors, conference leaders, and the NCAA.  “This is not just another proposal; it's a targeted solution designed to bring predictability, fairness, and long-term balance to a system that has rapidly evolved without structure. “The SCORE Act is built around three core principles:  Clarity: by establishing a national standard that replaces the current patchwork of state laws Stability: by setting reasonable guardrails around the transfer portal and NIL deals to protect both athletes and programs, and Support: by ensuring benefits like scholarship protections and financial literacy programs are not optional but expected. “For too long, student-athletes have operated in a gray area, empowered in some ways but exposed in others. The current model lacks the transparency and consistency that both athletes and institutions need. The SCORE Act brings that balance. “And while today’s hearing is just the beginning of a broader tri-committee process, with the Committees on Judiciary and Education & Workforce, it’s an important step. We are not here to micromanage college sports. We are here to put forward a framework that strengthens it — that ensures athletes can succeed on the field without losing sight of their futures off of it. “I am proud of the work this subcommittee has done on this issue, and I look forward to working with my colleagues on both sides of the aisle to get this across the finish line. And Go Gators!” ###

WASHINGTON, D.C. – Today, Congressman Gus Bilirakis (FL-12), Chairman of the Subcommittee on Commerce, Manufacturing, and Trade, led a hearing titled Winning Off the Field: Legislative Proposal to Stabilize NIL and College Athletics. “College athletics are a vital part of American culture, and it's clear—from both student-athletes and universities—that a national framework is long overdue. The Student Compensation and Opportunity through Rights and Endorsements (SCORE) Act delivers the stability, clarity, and transparency that stakeholders have been calling for,” said Chairman Bilirakis . “I’m proud of the work our Subcommittee has done on this important issue, and I look forward to advancing a measure that establishes clear guardrails—ones that empower student-athletes while upholding the core educational mission of our colleges and universities. ” Watch the full hearing here . Below are key excerpts from today’s hearing: Congresswoman Diana Harshbarger (TN-01): “Do you think these revenue sharing agreements will bring stability to college athletic rosters?” Ms. Montgomery: “I do think that it will bring a level of stability. [...] It's able to bring in some of those collective actions—some of those opportunities that we've seen previously—in house to make sure there is no nefarious activity going on.” Congressman Gabe Evans (CO-08): “In this conversation, some folks have proposed the creation of a federal self-regulatory organization, or some other sort of independent body to oversee college sports, including NIL. So just curious, in your view, do you think this is necessary or unnecessary? What mechanisms are already in place, and how do we ensure fair play and athlete protection without creating a new layer of bureaucracy?” Mr. King : “I do not think that we need federally created commission. You've heard talk about the College Sports Commission, which arises out of the House settlement. Now that it's approved, it is actually in existence and up and running, and the way it is structured is it would, it will handle the regulation.” Congresswoman Russell Fry (SC-07): “The NCAA and conferences have the ability to govern college athletes, but it's been diminished. You can’t create rules. You can’t enforce the rules that you create. [...] Can you explain the SEC’s ability to regulate and govern its member institutions, particularly on matters related to NIL?” Mr. King: “In order to have national competitions, you need to have uniform standards nationally.”

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, released the following statement following the Environmental Protection Agency’s announcement to address harmful regulations for power plants, commonly known as “Clean Power Plan 2.0” and Mercury and Air Toxics Standards (MATS). “I was proud to stand with Administrator Zeldin today as he announced these measures which are a victory for reliable and affordable energy. Enacted by the Biden-Harris Administration, these are just two of the burdensome rules that were part of a far-left regulatory agenda that jeopardized grid reliability and drove up prices for American families and businesses.” said Chairman Guthrie. “Attempting to push baseload power sources, including coal, oil, and natural gas, offline puts our national security at risk and threatens the US economy. By addressing these regulations, President Trump and his administration are working to once again unleash American energy to secure our grid and help provide the power we will need to win the race for AI."

WASHINGTON, D.C.  – Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, delivered the following opening statement at today’s hearing titled  Made In America: Strengthening Domestic Manufacturing And The Health Care Supply Chain. Subcommittee Chairman Carter's opening statement as prepared for delivery: “Today’s hearing is critical in addressing our nation’s reliance on adversarial countries for essential medications and health care products. This dependence not only jeopardizes our national security and patient safety, but also highlights the urgent need to increase domestic and friend-shored manufacturing. “Let me be clear: the United States should never be dependent on the Chinese Communist Party for the antibiotics and essential medicines. But that’s exactly the dangerous position we are in today. “In 2002, the United States manufactured 72 percent of the pharmaceuticals it consumed. By 2023, that number had dropped to just 37.5 percent. We didn’t just outsource manufacturing—we outsourced the sovereignty and safety of our health care system. “We saw the impacts of this reliance firsthand during the COVID-19 pandemic. According to a conversation I had with the Administration for Strategic Preparedness and Response, or ASPR, under the Trump Administration, the United States saw a downtick in the amount of PPE and pharmaceuticals coming to our country from China in the fall of 2019. We didn’t learn about COVID-19 until January 2020. “China knew there was an unidentified sickness in its own country, concealed it, and then withheld medical supplies so the United States was less prepared when COVID-19 hit our shores. “As both a pharmacist and a member of Congress, I know how critical these medicines and supplies are — especially for our national security. Under the Biden-Harris Administration, over 323 drugs were in shortage during the first quarter of 2024 – an all-time high – and cancer patients were often forced to switch treatments, adjust dosage regimens, or, in extreme cases, unable to receive their lifesaving medications. There was no comprehensive effort to support American manufacturers or reduce our reliance on foreign supply chains. “That is unacceptable. “Thankfully, President Trump is taking meaningful action by demanding real investment in our domestic production base and putting an end to decades of failed “America Last” policies that left our supply chains hollowed out and put our patients, constituents, and families at risk. “Under the leadership of President Trump, we are bringing manufacturing back to America. Since the start of this year – the start of President Trump’s second term – Johnson & Johnson broke ground on a new $2 billion facility in North Carolina, Amgen announced a $900 million manufacturing expansion in Ohio, AbbVie committed $10 billion to invest in the United States, and Sanofi announced plans to invest at least $20 billion.  “And these are just a few examples. This is just the start.  “I look forward to hearing from my other colleagues about the recent investments in their Districts and States during this hearing today, and I am thrilled to see what additional investments continue to flow and thrive under an Administration focused on unleashing innovation and bringing capacities back home.  “Along those lines, I commend recent efforts by this Administration to bolster domestic production, but we must do our part in Congress as well. This hearing will make it clear that more can be done to eliminate burdensome regulatory barriers, streamline processes that impede our competitiveness on the global stage, and establish the proper incentives to ensure we are creating the environment to allow innovation to flourish.  “It is no coincidence that Georgia – the No. 1 state in the nation to do business – is home to Manus Bio, who has invested nearly $60 million and created over 100 jobs with the acquisition of a new manufacturing facility in Augusta. We need more policies at the federal level that mirror the pro-growth examples we have in the state of Georgia.  “That is why House Republicans passed the One Big Beautiful Bill Act, which incentivizes domestic medical supply production by rewarding companies that build their products in America, like USAntibiotics, who is the last remaining end-to-end domestic U.S. manufacturer of amoxicillin, the most prescribed antibiotic in the country.  This is about protecting American lives, empowering American workers, restoring American sovereignty, and reinforcing U.S. leadership in medical innovation. “China is not our friend. Every product component that then turns into a vial of medicine or a piece of medical equipment that is made in China is a missed opportunity to strengthen our economy and protect our people. “It is time to act. We need to view pharmaceutical and health care supply chain independence just as we are viewing energy independence. I am proud to stand with President Trump and all those committed to putting America First in our health care system—starting with the medicines we rely on every day.” ###

WASHINGTON, D.C. – Today, the House Committee on Energy and Commerce Subcommittee on Environment held a hearing titled Short-Circuiting Progress: How the Clean Air Act Impacts Building Necessary Infrastructure and Onshoring American Innovation. “Today’s hearing made it clear that bureaucratic red tape has limited our ability to expand American manufacturing,” said Chairman Griffith. “As we heard from our witnesses, Congress needs to take commonsense actions to ensure the Clean Air Act works as intended while not hampering our country’s retention of steady, well-paying jobs, or limiting our ability to lead in manufacturing innovation.” Watch the full hearing here . Below are key excerpts from today’s hearing: Congressman Buddy Carter (GA-01): “Balancing America's air quality with economic development begins with implementing common sense legislation. I think we would all agree on that. The EPA reviews the national ambient air quality standards, and on, on a five-year interval after establishing a national ambient air quality standard states assumed the primary responsibility for implementing it and enforcing these rules. This is an extremely time-consuming process, one that takes years and years. I've got a bill. It's called the CLEAR Act. Now we give states the time needed to implement standards without rushing the process, and I think that's very important. This bill also allows states the opportunity to correct deficiencies found by EPA and state implementation plans for NAAQS before EPA can issue a federal implementation plan. The CLEAR Act offers common sense solutions to make containing clean air standards realistic while giving states the time necessary to comply. Congressman John Joyce, M.D. (PA-13): “Important context for this hearing is understanding that America's air quality is among the best in the world, and that the U.S. emissions have steadily decreased over the past several decades, even as economic input and output has changed. We observed this trend because of the fact that reasonable clean air standards lead to economic growth and that this economic growth spurs innovation and investment in technology that ultimately reduces emissions without sacrificing output. We need to balance public health and clean air goals with the reality that unattainable standards will not only hurt the American economy, but also disincentivize development of the more efficient technologies necessary to continue to lower U.S. emissions.” Congresswoman Mariannette Miller-Meeks (IA-01): “The United States has proven that environmental progress and economic growth aren't mutually exclusive. We've dramatically improved air quality while expanding energy output in Iowa, our farmers and manufacturers rely on stable smart policy to keep innovating and growing and also to compete economically around the globe. As we look to the future. any new regulations must support, not stifle, the backbone industries of our heartland.”

WASHINGTON, D.C. – Today, Congressman Earl L. "Buddy Carter" (GA-01), Chairman of the Subcommittee on Health, led a hearing titled Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain. “Under the leadership of President Trump, we are bringing manufacturing back to America,” said Chairman Carter. “ Since the start of this year – the start of President Trump’s second term – Johnson & Johnson broke ground on a new $2 billion facility in North Carolina, Amgen announced a $900 million manufacturing expansion in Ohio, AbbVie committed $10 billion to invest in the United States, and Sanofi announced plans to invest at least $20 billion. And these are just a few examples; this is just the start.” Watch the full hearing here . Below are key excerpts from today’s hearing: Congressman Buddy Carter (GA-01): “If Congress were to act on the recommendations today, how quickly could our domestic capacity expand? If we were to act on this, how quickly can we get this up and running?” Mr. Cashman: “With the right policy framework, we could significantly expand production with 18 to 24 months. We're currently running three active production lines; we have two crews on first shift and another crew on second shift. By simply adding new crews, to adding shifts so we can have three shifts per day on each line, we could dramatically increase our production.” Congressman Troy Balderson (OH-12): “ We know that a recent analysis showed that around half of the active pharmaceutical ingredients (APIs) for prescription medications in the U.S come from India and the EU. With around 12 percent being manufactured domestically here in the U.S. from your perspective and with your great experience, how do you believe we can increase the share in a sustainable way?” Dr. Piervincenzi: “I think the first layer is to increase the production of API, [which] will require new facilities and substantial new investments and time. There are shorter term ways to bridge the gap and to create a more secure supply chain, including through friend shoring and other purchasing opportunities. And finally, also considering the potentially even higher vulnerability to the starting materials upstream of the APIs, which may be even more highly concentrated in adversary countries and coming to the U.S. through India and Europe.” Congressman Jay Obernolte: (CA-23): “One of the things [Mr. Cashman] suggested was long-term supply contracts, but if you are someone that has consistent demand for a drug like amoxicillin, and you've experienced a situation where supply is constrained and therefore the market reacts by raising prices up to astronomical levels, you would think that would incentivize you, just from a financial perspective, to diversify your supply chains.”